ClinicalTrials.gg
RecruitingNCT07305207Updated Aug 27, 2026

Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness

A Phase 1 interventional study of Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study. in Influenza (Healthy Volunteers), sponsored by Dalhousie University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Dalhousie University · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies in Influenza, Human with a site in Canada — 7 open to participants now, 12 under way, 4 of them phase 3. Influenza, Human · Canada.

Planned enrollment
124th of 131
32 · median 300
Started
2026
with 4 others
Phase 1
15 of 157
1 open now
Primary completion
2027-06
later than 7 of 11 live
Registered
155th of 157
by date
Lead sponsor
6 of 157
Dalhousie University

Among the 157 studies in Influenza, Human with a site in Canada, this one is the 124th largest by planned enrollment of the 131 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 155th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 157 studies in Influenza, Human with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Influenza, Human with a site in Canada, or all of them as a file.
02

Study summary

The overall objective is to establish an influenza Controlled Human Infection Model (CHIM) in Canada that can be used to assess the safety and efficacy of candidate vaccines, biologics, and therapeutics targeting influenza viruses.

03

Conditions studied

  • Influenza (Healthy Volunteers)

Browse trials for

Keywords

  • human challenge
  • Controlled human infection model
  • Influenza
  • intranasal challenge
  • Phase 1 clinical trial
  • Immune response
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained from the participant.
  2. 18-45 years of age.
  3. Good general health status, as determined by history and physical examination conducted no longer than 30 days prior to the challenge date.
  4. HAI antibody titer ≤1:40 against influenza A/Texas/71/2017 (H3N2).
  5. Eligibility laboratory values* (complete blood cell count with differential (CBC-D), biochemistry (creatinine (Cr), total , blood urea nitrogen (BUN), aspartame aminotransferase (), alanine transaminase (ALT), and c-reactive protein (CRP))*Labs within normal range or grade 1 abnormalities deemed not by a study investigator are considered acceptable.
  6. Vital signs** as follows:

    1. Pulse is 47 to 99 beats per minute
    2. Systolic blood pressure is 85 to 139 mmHg
    3. Diastolic blood pressure is 55 to 89 mmHg
    4. SpO2 ≥ 95%; RR ≤ 18
    5. Oral temperature is less than 38.1°C **Clinical judgement when characterizing vital signs will be used in the context of certain populations according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (e.g. conditioned athletes, white coat hypertension etc.)
  7. If a person is at risk of becoming pregnant, has practiced adequate for 28 days prior to challenge, and has a negative pregnancy test on the screening day and the day before influenza A/H3N2 challenge (Check-in Day) and has agreed to continue adequate contraception until 60 days after challenge.

    Risk of pregnancy is defined as any individual assigned female at birth or with reproductive capacity who is sexually active with individuals with sperm-producing capabilities. Individuals who have received the following are considered to not have reproductive capacity:

    • Documented hysterectomy
    • Documented bilateral salpingectomy
    • Documented bilateral oophorectomy
    • Documented and current bilateral tubal ligation or occlusion
    • Credible self-reported history of diagnosed infertility
    • Hormone therapy (e.g. testosterone), provided it is administered consistently and medically assessed as sufficient to reduce pregnancy such that ovulation has ceased
    • Any other condition, as determined by the Principal Investigator/study physician, that would render an individual incapable of becoming pregnant

    Adequate contraception is defined as a contraceptive method with a failure rate of \<1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable CI2403.03November2025_V3.0 52
    • Intra-uterine device (IUD) with or without hormonal release
    • Vasectomized partner, if this is the participant's sole partner and the partner has received a medical assessment of the surgical success
    • Credible (as deemed by the Investigator/study physician) self-reported history of abstinence for at least 28 days prior to challenge
  8. Participants who, in the opinion of the Investigator/study physician, can and will comply with the requirements of the protocol (e.g., inpatient stay, complete eDiary Cards, return for follow-up visits).

Exclusion criteria

Exclusion Criteria:

  1. Underlying chronic medical condition requiring ongoing follow-up and monitoring by a physician (e.g., diabetes, seizure disorder).
  2. Underlying renal disease or disorders requiring ongoing follow-up and monitoring by a physician. In the event a participant has a minimally elevated BUN and/or Cr at screening, the participant will either be excluded or an eCRF or may be conducted to determine eligibility.
  3. Underlying coagulation disorder history. In the event a participant reports a personal history of undiagnosed prolonged bleeding and/or recurrent nosebleeds or a personal or family history of coagulation disorders, a bleeding panel (, INR, fibrinogen) will be used to rule out coagulopathy.
  4. Underlying cardiac conditions including:

    1. Hypertension, angina, or prior myocardial infarction
    2. Structural or functional cardiac disease (e.g., dilated cardiomyopathy, congestive heart failure)
    3. With a history of arrhythmias/dysrhythmias (e.g., torsades de pointes, atrial fibrillation)
    4. Cardiac conduction abnormalities (e.g., congenital or acquired heart block)
    5. Uncorrected or ongoing serum electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia)
  5. Underlying pulmonary disease including asthma, emphysema, chronic bronchitis, pulmonary tuberculosis or any other structural or functional pulmonary condition (e.g., history of severe airway hyper-responsiveness).
  6. /FEV6 \< 0.73 as an indication of potential airflow limitation.
  7. Known allergy to in the challenge virus inoculum and placebo. The excipient (diluent and placebo) is SPG: sucrose, KH2PO4, K2HPO4, L-glutamic acid.
  8. Moderate or severe symptoms of health anxiety, anxiety, and mood symptoms. Self-reported current diagnosis of a major psychiatric illness, including, but not limited to, a schizophrenia spectrum disorder, bipolar disorder, posttraumatic stress disorder, obsessive compulsive disorder, substance use disorder, or eating disorder, based on standardized mental health screening tools.
  9. Habitual*** smoker of tobacco, e-cigarettes or marijuana. ***Habitual smokers are those who smoke more than four cigarettes, other tobacco products, e-cigarettes (to include vaping and Juuling products) or marijuana in a week and cannot agree to abstain from smoking cigarettes, other tobacco products, e-cigarettes and/or marijuana products during participation in the study.
  10. Any current daily use of illicit drugs whereby the individual and/or study staff assess that the individual cannot abstain from during the isolation period.
  11. Any current daily alcohol consumption whereby the individual and/or study staff assess that the individual cannot abstain during the isolation period.
  12. History of allergic rhinitis and/or any condition that causes similar symptoms, including chronic cough.
  13. Pregnant (known before or established at the time of screening using a urine pregnancy test) or breastfeeding.
  14. (with /AIDS or receiving immunosuppressive therapy involving ) or any medical condition or medication that leads to a compromised immune system.
  15. Screening blood work positive for , , or HIV.
  16. Influenza virus detected in NPS sample prior to challenge using RT-qPCR and/or culture isolation, or detection of other respiratory infection.
  17. Received influenza vaccination within the last 4 months prior to screening based on history described by participant or planned receipt up to Study Day 57.
  18. Living with, working with, or in close contact with children less than 6 months of age, or a household member(s) highly recommended to receive an annual influenza vaccination by NACI**** and that have not been immunized with influenza vaccine within the last year or immunized less than 3 weeks prior to challenge.

    ****Individuals that are highly recommended by NACI to receive an influenza vaccine and potentially at risk include the following (52): (52):

    1. All children 6-59 months of age
    2. Adults and children with the following chronic health conditions:

    i. Cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis and asthma) ii. Diabetes mellitus and other metabolic diseases iii. Cancer, immune compromising conditions (due to underlying disease, therapy, or both, such as solid organ transplant or hematopoietic stem cell transplant recipients) iv. Renal disease v. Anemia or hemoglobinopathy vi. Neurologic or neurodevelopmental conditions (includes neuromuscular, neurovascular, neurodegenerative, neurodevelopmental conditions and seizure disorders [and, for children, includes febrile seizures and isolated developmental delay], but excludes migraines and psychiatric conditions without neurological conditions) vii. Morbid obesity (defined as (BMI) ≥ 40 kg/m2) viii. Children six months to 18 years of age undergoing treatment for long periods with acetylsalicylic acid, because of the potential increase of Reye syndrome associated with influenza c. All individuals who are pregnant d. All individuals of any age who are residents of nursing homes and other chronic care facilities e. Adults 65 years of age and older f. Indigenous Peoples

  19. Any to receiving oseltamivir or zanamivir including known history of negative/anaphylactic reactions. Inability to take capsules containing gelatin or sorbitol (oseltamivir) or lactose-intolerant (zanamivir)
  20. Recent (within the 6 months before Screening Day) nasal or sinus surgery or diagnosis with nasal polyps.
  21. Recent use (4 weeks of Screening Day) of intranasal steroids, antihistamines, or any substance (including legally prohibited or prescription drug) that is administered nasally.
  22. Receipt of any drug or vaccine within 6 months prior to challenge. An investigational drug or vaccine is one that is still being tested in clinical trials that has not yet been authorized for use in Canada for administration by public programs.
  23. Receipt of any authorized vaccines within 2 weeks prior to being challenged.
  24. Previous moderate or severe laboratory-confirmed SARS-CoV-2/COVID-19, influenza infection, or any other respiratory virus infection (e.g., RSV) that required hospitalization.
  25. Head trauma (e.g., fracture of the cribriform plate) within 1 year of screening.
  26. Symptoms indicative of acute respiratory illness (such as fever, cough, difficulty breathing) identified during the physical examination done on Study Day -1 (check-in) or Day 1 before a participant is challenged. In the event a participant reports changes to their medical history since screening up until check-in, a history-directed respiratory panel will be administered and any positive respiratory virus including SARS-COV-2 will be exclusionary
  27. History of Bell's Palsy, Guillain-Barre, and/or facial paralysis.
  28. Receipt of facial cosmetic filler, or any facial neuromodulator, in the past 3 months.
  29. Self-reported sleep apnea that requires a continuous positive airway pressure (cPap) machine
  30. Receipt of blood or blood products during the six months prior to the planned date of challenge.
  31. Plans to donate blood anytime throughout the study.
  32. Any other finding that the Investigator/study physician considers will make the participant unsuitable for the study or unable to comply with the study requirements.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Experimental: Group 1: Dose Number 1 (10^5)

    Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo

    Biological: Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.

  • Experimental
    Experimental: Group 1: Dose Number 2 (10^4)

    Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo

    Biological: Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.

  • Experimental
    Experimental: Group 1: Dose Number 3 (10^6)

    Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo

    Biological: Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.

Interventions

06

What researchers measure

Primary outcomes

  1. Symptomatic influenza-virus infection

    Viral shedding (as determined by a detectable quantitative RT-qPCR result on at least two days and/or at least one positive culture) beginning 24 hours after challenge (Study Day 2) until Study Day 8 and a cumulative symptom score of ≥6 from daily component symptoms computed across any consecutive 5-day window starting on Study Day 2 up to Study Day 8 post-challenge using a Modified Jackson Score (MJS).

    Time frame: Study Day 2 until Study Day 8

Secondary outcomes

  1. Compare rates of symptomatic influenza-virus infection across doses administered.

    Rate of symptomatic influenza-virus infection at each challenge dose group administered

    Time frame: Study Day 1 up to Study Day 29

  2. Establish the safety profile of a live recombinant influenza strain RG-A/Texas/71/2017 (H3N2, Clade 3C3a) following challenge in healthy adult volunteers.

    Percent of unsolicited adverse events (AEs) reported from challenge to Study Day 29. Percent of solicited AEs, specifically Grade 3 or 4 adverse reactions (ARs), defined as signs and symptoms of influenza reported from challenge to Study Day 29. Percent of medically attended adverse events (MAAEs) reported from challenge to Study Day 57. Percent of serious adverse events (SAEs) reported from challenge to Study Day 85. Percent of influenza disease with serious complications (Adverse events of special interest (AESI)) reported from challenge to Study Day 29.

    Time frame: Study Day 1 up to Study Day 85

  3. Assess the viral shedding

    Percent of participants within a challenge dose group with detected viral shedding in NPSs post-challenge from Study Day 2 onwards using culture and/or RT-qPCR.

    Time frame: Study Day 1 up to Study Day 85

  4. Assess the peak viral load

    Magnitude of viral shedding post-challenge in each participant, defined as the peak viral load in NPSs from Study Day 2 onwards using RT-qPCR.

    Time frame: Study Day 1 up to Study Day 85

  5. Measure the duration of the viral shedding

    Duration of viral shedding defined as the number of days from first positive RT-qPCR to last positive RT-qPCR where virus is detected in NPSs post-challenge from Study Day 2 onwards.

    Time frame: Study Day 1 up to Study Day 85

  6. Determine the timing, magnitude, and nature of humoral immune responses (hemagglutinin inhibition (HAI) and microneutralization (MN) titers) post-challenge.

    Percent of participants with serological conversion defined as a minimum 4-fold rise in post-challenge serum antibodies (by HAI ) to influenza infection at Study Days 15, 29, 57, and 85 post-challenge compared to baseline.

    Time frame: Study Day 1 up to Study Day 85

  7. Evaluate the association of culture and/or RT-qPCR-positivity with symptomatic influenza-virus infection.

    Correlation of virus culture and virus RT-qPCR with assigning symptomatic influenza-virus infection as the clinical outcome.

    Time frame: Study Day 1 up to Study Day 8

  8. Explore the perspectives of Investigators and staff in fostering equitable, diverse, inclusive, and accessible (EDIA) participation in CHIM trials through a qualitative study using questionnaires

    Obtain and summarize viewpoints of Investigators and staff through questionnaires on participant equity, diversity, inclusion, and accessibility in CHIM trials.

    Time frame: Study Day 1 up to Study Day 85

Other outcomes

  1. Determine optimal collection time points for biological specimens to assess mucosal and systemic cellular responses to influenza infection (in nasopharyngeal swabs (NPSs), nasal washes (NWs), serum, saliva secretions, peripheral blood) post-challenge.

    Peak magnitude in unit of detection or unit of concentration (e.g., antibody titer), among all study days on which the samples are collected and tested.

    Time frame: Study Day 1 up to Study Day 85

  2. Compare detection of virus by culture and by RT-qPCR.

    Correlation of virus culture and virus RT-qPCR with determining positive infection status by detection of viral shedding in participants challenged with virus.

    Time frame: Study Day 1 up to Study Day 8

  3. Evaluate effects of age, sex, gender, ethnicity, baseline antibody titers, and prior receipt of seasonal influenza vaccine on SII.

    Correlation of age, sex, gender, ethnicity, baseline antibody titers, and prior receipt of seasonal influenza vaccine with assigning SII as the clinical outcome.

    Time frame: Study Day 1 up to Study Day 85

  4. Describe serum neuraminidase inhibition (NAI) antibody responses post-challenge

    Percent of participants with serological conversion defined as a minimum 4-fold rise in post-challenge NAI serum antibodies to influenza infection at Study Days 15, 29, 57, and 85 post-challenge compared to baseline.

    Time frame: Study Day 1 up to Study Day 85

  5. Evaluate mucosal IgA immune response at baseline and post-challenge.

    Percent of participants with increased nasal IgA from baseline to latest time points available post-challenge.

    Time frame: Study Day 1 up to Study Day 85

  6. Evaluate serum and mucosal cytokine and chemokine levels at baseline and post-challenge.

    Percent of participants with change in levels of A/Texas/71/2017/H3N2 induced systemic and mucosal cytokine and chemokine responses from baseline to time points available post-challenge.

    Time frame: Study Day 1 up to Study Day 85

  7. Determine the timing of cellular immune responses at baseline and post-challenge and correlate with the clinical status of participants

    Time of detection, by Study Day, of immune response(s) associated with the different types of immune cells, or cell subsets.

    Time frame: Study Day 1 up to Study Day 85

  8. Determine the magnitude of cellular immune responses at baseline and post-challenge and correlate with the clinical status of participants.

    Peak magnitude, by Study Day, of immune response(s) associated with the different types of immune cells, or cell subsets.

    Time frame: Study Day 1 up to Study Day 85

  9. Determine the nature of cellular immune responses at baseline and post-challenge and correlate with the clinical status of participants

    Percent of participants within a challenge dose group with immune response(s) associated with the different types of immune cells, or cell subsets. Percent of participants within a clinical outcome (Non-infected, Asymptomatic, or SII) with immune response(s) associated with the different types of immune cells, or cell subsets.

    Time frame: Study Day 1 up to Study Day 85

  10. Compare the clinical features of four groups of participants

    Proportions and Generalized Linear Mixed Models (GLMM) of solicited influenza signs symptoms (individually and grouped by body system) plotted over days post-challenge, comparing the four groups of participants while controlling for age, sex, gender, serostatus, and ethnicity, where feasible

    Time frame: Study Day 1 up to Study Day 85

  11. Explore alternative case definitions (e.g., mild to moderate influenza disease, influenza like illness) and clinical assessment tools (i.e., Modified Jackson Score, FLU-PRO) for symptomatic RT-qPCR-positive influenza infection.

    Correlation of different case definitions of influenza disease using different clinical assessment tools with symptomatic RT-qPCR -positive influenza infection.

    Time frame: Study Day 1 up to Study Day 85

  12. Assess the association of human leukocyte antigen (HLA) class I and II alleles with clinical, immune and virologic outcomes

    Correlation of (HLA) class I and II alleles with clinical, immune, and virologic outcomes

    Time frame: Study Day 1 up to Study Day 85

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 54 non-industry phase 1 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 26, 2025
StartActual
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jan 31, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305207
Lead sponsor
Dalhousie University
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Jun 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Nick Bartlett
Contact
nicholas.bartlett@iwk.nshealth.ca
902-470-8141
Hannah Munday
Contact
hannah.munday@iwk.nshealth.ca
902-470-8141

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Influenza A virus subtype H3N2

Start the discussion